Skip to Content

Possia

Active Substance: ticagrelor
Common Name: ticagrelor
ATC Code: B01AC24
Marketing Authorisation Holder: AstraZeneca AB
Active Substance: ticagrelor
Status: Withdrawn
Authorisation Date: 2010-12-03
Therapeutic Area: Peripheral Vascular Diseases Acute Coronary Syndrome
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

The marketing authorisation for Possia has been withdrawn at the request of the marketing-authorisation holder. 

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide